The SURMOUNT Trial Program: Tirzepatide for Weight Management

The SURMOUNT program comprises multiple trials (SURMOUNT-1, -2, -3, and others) designed to evaluate tirzepatide's efficacy and safety for weight management across diverse populations. These trials enrolled adults with obesity (body mass index ≥30 kg/m²) or with overweight (BMI ≥27 kg/m²) and at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia. The trials included individuals both with and without established type 2 diabetes, allowing evaluation of tirzepatide's weight management effects across different metabolic backgrounds.

Each trial employed a randomised, double-blind, placebo-controlled design—the gold standard in clinical research. Participants were randomly assigned to receive either tirzepatide or placebo, with neither participants nor researchers knowing assignment until after the trial. This design eliminates bias and allows for rigorous assessment of tirzepatide's true effect.

SURMOUNT trials typically involved a 52-week primary treatment phase followed by optional extension periods. Tirzepatide was administered as a once-weekly subcutaneous injection, with doses escalated over the first weeks to reach target maintenance doses. The escalation approach allowed tolerability assessment and reduced early side effects. Participants received lifestyle counselling (dietary advice and physical activity recommendations) as part of standard care, alongside either tirzepatide or placebo.

The primary endpoint in SURMOUNT trials was the change in body weight from baseline to week 52. Secondary endpoints included the proportion of participants achieving at least 5%, 10%, 15%, and 20% weight loss—clinically meaningful thresholds associated with metabolic health improvements. Metabolic parameters such as HbA1c, fasting glucose, lipid profiles, and blood pressure were measured, as were safety assessments including adverse event rates and laboratory evaluations.

The SURMOUNT trials reported substantial weight loss with tirzepatide. At the highest maintenance dose (15 mg weekly), participants receiving tirzepatide achieved weight loss of approximately 21-22% of baseline body weight over 52 weeks. This far exceeded the placebo group, which experienced minimal weight change or modest weight gain. Intermediate doses (5 mg and 10 mg weekly) produced dose-dependent weight loss of approximately 12-16% at the 5 mg dose and 16-18% at the 10 mg dose.

These results markedly exceeded outcomes reported with GLP-1-only agonists in comparable trials. For example, semaglutide at its highest approved weight management dose achieved approximately 13-14% weight loss, numerically less than tirzepatide at equivalent doses. This comparison provided clinical evidence supporting the dual-agonism hypothesis and demonstrated tirzepatide's superiority for weight reduction.

Secondary endpoints revealed the magnitude of weight loss response. In SURMOUNT-1, for instance, approximately 85% of tirzepatide recipients achieved at least 5% weight loss compared to approximately 35% of placebo recipients. Nearly 70% of tirzepatide recipients achieved at least 10% weight loss compared to approximately 20% of placebo. These proportions declined at higher thresholds but remained substantially above placebo across all clinically meaningful categories.

Metabolic parameters improved with tirzepatide. HbA1c—a measure of average blood glucose control—decreased by approximately 0.5-1.0 percentage points with tirzepatide versus minimal change with placebo. Fasting glucose, lipid profiles, blood pressure, and markers of insulin resistance all improved significantly. These metabolic improvements were particularly pronounced in participants with baseline dysglycaemia or type 2 diabetes, supporting tirzepatide's dual efficacy in weight and glucose management.

Gastrointestinal adverse events were the most frequently reported side effects. Nausea was experienced by approximately 25-33% of tirzepatide recipients versus 5-10% of placebo. Vomiting occurred in approximately 5-10% of tirzepatide recipients versus 1-2% of placebo. Diarrhoea and constipation were also more common with tirzepatide. These events were generally mild to moderate and tended to diminish over time as the body adapted to the medication.

Serious adverse events were uncommon in SURMOUNT trials and did not occur at meaningfully higher rates with tirzepatide compared to placebo. No increases in pancreatitis, acute kidney injury, or other serious metabolic events were observed. Hypoglycaemia (low blood glucose) was very rare with tirzepatide monotherapy and occurred at similar rates as placebo. This glucose-dependent insulin secretion profile suggests tirzepatide carries minimal hypoglycaemia risk when used without concurrent insulins or sulfonylureas.

SURMOUNT trials were conducted over 52 weeks, providing robust one-year efficacy and safety data. However, longer-term data (beyond 2-3 years) regarding sustained efficacy, potential metabolic adaptation, or late-emerging safety signals remain limited. Extension phases of SURMOUNT trials are ongoing and will provide multi-year follow-up.

Additionally, SURMOUNT trials excluded individuals with a history of personal or family medullary thyroid carcinoma and those with multiple endocrine neoplasia type 2, due to animal data suggesting potential thyroid effects (though this has been under re-evaluation). The trials also enrolled predominantly non-Hispanic white and non-Hispanic Black participants; data in other ethnic groups remain more limited. Future trials enrolling more diverse populations will strengthen the evidence base.